Trial record 16 of 31 for:    "Hypoplastic left heart syndrome"

Ambrisentan in Single Ventricle

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified March 2014 by Duke University
Sponsor:
Information provided by (Responsible Party):
Kevin Hill, Duke University Medical Center
ClinicalTrials.gov Identifier:
NCT02080637
First received: February 21, 2014
Last updated: March 4, 2014
Last verified: March 2014
  Purpose

Purpose: To evaluate the pharmacokinetics, bioavailability and hemodynamic efficacy of ambrisentan after Fontan surgical palliation of single ventricle heart defects.

Study activities and population group: Children undergoing Fontan surgical palliation for single ventricle defects will be eligible for the study. Up to 20 subjects will be enrolled (16 ambrisentan, 4 placebo) and will receive 3 days (3 doses) of ambrisentan starting on post-operative day #1 upon returning from the operating room. Ambrisentan plasma levels will be obtained at specified time points during treatment. Post-operative monitoring lines will be used to measure effects of ambrisentan on hemodynamics and pulmonary / systemic endothelial function.


Condition Intervention Phase
Hypoplastic Left Heart Syndrome
Hypoplastic Right-sided Heart Complex
Drug: Ambrisentan
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric Patients

Resource links provided by NLM:


Further study details as provided by Duke University:

Primary Outcome Measures:
  • Plasma concentration of Ambrisentan [ Time Frame: Plasma samples collected at 0-1,1-6,18-30 and 40-60hrs after administration of the first ambrisentan dose. ] [ Designated as safety issue: Yes ]
    Change Plasma concentration of ambrisentan


Secondary Outcome Measures:
  • Amount and duration of chest tube drainage post Fontan Operation [ Time Frame: Chest tube output will be measured daily for the duration of the post-operative hospitalization or for 30 days whichever is shorter. Chest tube duration will be calculated as the number of days from placement to removal. ] [ Designated as safety issue: No ]
    Collect these data to assess whether ambrisentan improves post-operative outcomes.

  • Change in hemodynamic parameters [ Time Frame: Hemodynamic evaluation performed prior to initiation of study drug and at 0-1,1-6,18-30 and 40-60hrs after administration of the first ambrisentan dose ] [ Designated as safety issue: No ]
    Hemodynamic data, including Fontan pressures and saturations, will be collected at the specified timepoints

  • Safety [ Time Frame: 30 days after last ambrisentan dose ] [ Designated as safety issue: Yes ]
    Adverse events will be collected during hospitalization and for 30 days after administration of the last ambrisentan dose


Estimated Enrollment: 20
Study Start Date: February 2014
Estimated Study Completion Date: February 2016
Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ambrisentan
Oral ambrisentan 2.5 - 5 mg, single dose, once daily
Drug: Ambrisentan
Once daily oral dosing
Other Name: Leitaris
Placebo Comparator: Placebo
Oral placebo 2.5 - 5 mg, single dose, once daily

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   24 Months to 120 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 24 months; ≤120 months.
  2. History of congenital heart disease with severe hypoplasia of a right or left ventricle.
  3. Undergoing Fontan surgery as part of standard clinical care.
  4. Availability and willingness of the parent/legally authorized representative to provide written informed consent and, as appropriate, assent from the child.

Exclusion Criteria:

  1. History of serious adverse event related to ambrisentan administration.
  2. History of ambrisentan exposure within 48 hours of the study.
  3. Presence of pulmonary venous obstruction.
  4. Treatment with cyclosporin.
  5. Any of the following - as determined by the attending physician

    • Significant hemodynamic instability
    • Sepsis.
    • Need for ECMO support.
  6. Renal failure defined as serum creatinine > 2 times higher than the upper limit of normal.
  7. Liver dysfunction defined as alanine aminotransferase or aspartate aminotransferase > 3 times higher than the upper limit of normal.
  8. Thrombocytopenia defined as a platelet count < 50 000 cells/µL.
  9. Leukopenia defined as white blood cells < 2500 cells/µL.
  10. Anemia defined as hemoglobin < 8mg/dL.
  11. Atrial hypertension (mean LA pressure > 12mm Hg).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02080637

Contacts
Contact: Kevin Hill, MD 919-681-2880 kevin.hill@dm.duke.edu
Contact: Mingfen Xu, MSN 919-668-6352 mingfen.xu@duke.edu

Locations
United States, North Carolina
Duke Universtiy Hospital Not yet recruiting
Durham, North Carolina, United States, 27710
Contact: Mingfen Xu, MSN    919-668-6352    mingfen.xu@duke.edu   
Sponsors and Collaborators
Kevin Hill
Investigators
Principal Investigator: Kevin Hill, MD Duke University
  More Information

No publications provided

Responsible Party: Kevin Hill, Assist Professor, Duke University Medical Center
ClinicalTrials.gov Identifier: NCT02080637     History of Changes
Other Study ID Numbers: Pro00050118
Study First Received: February 21, 2014
Last Updated: March 4, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Duke University:
Single ventricle

Additional relevant MeSH terms:
Hypoplastic Left Heart Syndrome
Dextrocardia
Cleft Palate
Heart Defects, Congenital
Microcephaly
Micrognathism
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities
Situs Inversus
Jaw Abnormalities
Jaw Diseases
Musculoskeletal Diseases
Maxillofacial Abnormalities
Craniofacial Abnormalities
Musculoskeletal Abnormalities
Stomatognathic Diseases
Mouth Abnormalities
Mouth Diseases
Stomatognathic System Abnormalities
Malformations of Cortical Development
Nervous System Malformations
Nervous System Diseases

ClinicalTrials.gov processed this record on July 22, 2014